Showing 2831-2840 of 10545 results for "".
Dermwire TV: Topical Caffeine for Hair Growth, Tapinarof for Pediatric AD
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-topical-caffeine-for-hair-growth-tapinarof-for-pediatric-ad/48734/This episode highlights studies showing potential for topical caffeine in hair growth in patients with alopecia areata, as well as recent positive results for tapinarof cream 1% for children with AD. Also, Cutera CEO Taylor Harris talks with Practical Dermatology about the evolving needs of today’sNew Devices and Adaptogens
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39741/Jacqueline Watchmaker, MD, explores the intersection of medical devices and adaptogenic therapies in skincare. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: FDA Clears Roflumilast, Guselkumab for Pediatric Populations, Plus More
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-clears-roflumilast-guselkumab-for-pediatric-populations-plus-more/39732/This episode highlights two new important pediatric approvals for treatments in both atopic dermatitis and psoriatic disease, also features a clip from a recent YoungMD Connect (YMDC) mentorship session with Dr. Tina Bhutani covering both career paths in both academia and industry.The Battle of Biostimulators: PLLA vs Hyperdilute CaHA
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/the-battle-of-biostimulators-plla-vs-hyperdilute-caha/39250/Modern Aesthetics executive editor Kay Durairaj, MD, FACS, hosts a workshop describing the differences between two dermal filler options, and how she utilizes both in her practice. YoungMD Connect is an editorially independent platform made possible by industry sponsorships. We would like to thank oIncreased APS Risk for Psoriasis Patients, Plus More
https://practicaldermatology.com/series/dermwire-tv/increased-aps-risk-for-psoriasis-patients-plus-more/39299/This episode highlights research showing increased risk for anti-phospholipid syndrome (APS) in patients with psoriatic disease, as well as research showing increased risks for tuberculosis in patients treated with immunosuppressants. The episode also features a clip from an in-depth discussion arouBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitisGrowing into the Role of a KOL
https://practicaldermatology.com/programs/practical-dermatology/tbd/39738/Michael H. Gold, MD, founder/medical director of Gold Skin Care Center, shares his path and strategies becoming a key opinion leader in dermatology. This video was recorded at the Science of Skin Summit in Austin, TX.What’s New in Rosacea Treatments?
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39737/James Q. Del Rosso, DO, FAOCD, reviews the latest therapeutic innovations and evidence in rosacea management. This video was recorded at the Science of Skin Summit in Austin, TX.What’s New in Psoriasis
https://practicaldermatology.com/conferences/science-of-skin-summit-2025/tbd/39743/Chris Bunick, MD, FAAD, talks about new therapeutic directions, real‑world data, and challenges in psoriasis management. This video was recorded at the Science of Skin Summit in Austin, TX.DermwireTV: Deucravacitinib Maintains Efficacy in PsO at 3 Years
https://practicaldermatology.com/programs/practical-dermatology/dermwiretv-deucravacitinib-maintains-efficacy-in-pso-at-3-years/37249/In this episode of DermwireTV, deucravacitinib maintains efficacy for plaque psoriasis through 3 years in a new analysis; GLP-1 medications may be fueling a rise in aesthetic procedures, according to new research; and Drs. Tina Bhutani and Lisa Swanson weigh in on transitioning from academia to priv